The Bolar Provision under the Patents Act, 1970 is one of the most significant statutory defences available in India against a patent infringement suit, particularly in the pharmaceutical and biotechnology sectors, where regulatory approvals play a crucial role in bringing products to market. The provision reflects a careful balance between the exclusive rights granted to patent holders and the larger public interest in ensuring timely access to affordable medicines and technological innovations after the expiry of patent protection. Patent law grants inventors a temporary monopoly over their inventions, enabling them to prevent others from making, using, selling, offering for sale, or importing the patented product or process without authorization.
While these exclusive rights encourage innovation and reward investments in research and development, they can also create barriers to market entry if interpreted too broadly. One such barrier arises in industries where products require extensive regulatory approvals before commercialization. Without an exception such as the Bolar Provision, generic manufacturers would be compelled to wait until the expiry of the patent before commencing the process of obtaining regulatory approval, resulting in delays in the introduction of generic products and effectively extending the patent monopoly beyond its statutory term.
To address this issue, India incorporated the Bolar Exception through Section 107A of the Patents Act, 1970, thereby ensuring that activities undertaken solely for obtaining regulatory approval do not amount to patent infringement. The Bolar Provision derives its name from the landmark United States case of Roche Products Inc. v. Bolar Pharmaceutical Co., where a generic pharmaceutical company used a patented drug before patent expiry to conduct tests necessary for obtaining approval from the United States Food and Drug Administration (FDA).
The court initially held that such use constituted patent infringement. In response, the United States Congress enacted the Hatch-Waxman Act in 1984, introducing the Bolar Exception to permit limited use of patented inventions for regulatory purposes. Recognizing the importance of this principle, India incorporated a similar provision in Section 107A through the Patents (Amendment) Act, 2002, which was further refined through subsequent amendments. Section 107A(a) provides that any act of making, constructing, using, selling, or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law for the time being in force in India or in a country other than India that regulates the manufacture, construction, use, sale, or import of any product shall not be considered infringement.
This provision effectively creates a statutory exemption allowing competitors to undertake activities necessary for securing regulatory approvals before the expiry of a patent. The rationale behind the Bolar Provision is rooted in the objective of preventing unnecessary delays in market entry after patent expiry. Regulatory approval processes often require extensive testing, data generation, clinical studies, bioequivalence studies, stability studies, and submission of scientific information to regulatory authorities. These activities can take several months or even years to complete.
If generic manufacturers were prohibited from conducting such activities during the patent term, they would be unable to enter the market immediately upon patent expiry, thereby granting the patent holder a de facto extension of exclusivity beyond the legally prescribed period. The Bolar Provision ensures that generic manufacturers can complete the necessary regulatory requirements during the patent term and launch their products promptly once the patent expires. This promotes competition, reduces prices, and enhances public access to medicines and other regulated products. The scope of Section 107A is notably broad and extends beyond pharmaceuticals to any patented invention requiring regulatory approval.
The provision covers acts such as making, using, constructing, selling, or importing patented products if those activities are reasonably related to the development and submission of information required under regulatory laws. The phrase “reasonably related” is of particular importance because it defines the permissible scope of activities under the exemption. Courts generally interpret this phrase liberally to include activities genuinely connected with obtaining regulatory approval.
However, commercial exploitation of the patented invention under the guise of regulatory activities would not qualify for protection. The exemption applies not only to approvals sought in India but also to approvals sought in foreign jurisdictions. This international dimension is significant because it enables Indian manufacturers to prepare for global market entry and participate effectively in international pharmaceutical and biotechnology markets. One of the most influential judicial interpretations of the Bolar Provision in India came in Bayer Corporation v. Union of India and later in Bayer Corporation v. Natco Pharma Ltd., where courts emphasized the importance of balancing patent rights with public interest objectives.
However, the most comprehensive interpretation of Section 107A was provided by the Delhi High Court in Bayer Corporation v. Union of India and subsequently in Bayer Intellectual Property GmbH v. Alembic Pharmaceuticals Ltd. In Bayer Intellectual Property GmbH v. Alembic Pharmaceuticals Ltd., the dispute concerned whether the manufacture and export of a patented pharmaceutical product for purposes connected with obtaining regulatory approval in foreign countries fell within the scope of Section 107A. Bayer argued that large-scale manufacture and export exceeded the permissible limits of the Bolar Exception and constituted infringement.
Alembic contended that the exports were undertaken solely for regulatory purposes and were therefore protected by Section 107A. The Delhi High Court held that the Bolar Provision must be interpreted in a manner consistent with its legislative objective and recognized that exports intended solely for generating information required for regulatory approvals could fall within the exemption. The court emphasized that the focus should be on the purpose of the activity rather than its geographical location.
This judgment significantly strengthened the utility of Section 107A and confirmed India’s commitment to facilitating timely access to generic products. Another important case concerning the Bolar Provision is Merck Sharp and Dohme Corp. v. SMS Pharmaceuticals Ltd., where the Delhi High Court examined the extent to which activities undertaken for regulatory purposes could be protected under Section 107A. The court reiterated that the exemption is intended to facilitate regulatory compliance rather than commercial exploitation. Therefore, the burden often lies on the defendant to demonstrate that the activities in question were genuinely related to obtaining regulatory approvals.
The significance of the Bolar Provision extends beyond legal doctrine and has substantial economic, public health, and industrial implications. India is widely recognized as one of the largest producers of generic medicines in the world and plays a critical role in supplying affordable pharmaceuticals to both domestic and international markets. The Bolar Exception enables Indian pharmaceutical companies to conduct the necessary studies and obtain approvals before patent expiry, thereby ensuring uninterrupted availability of generic medicines once exclusivity ends. This contributes to lower healthcare costs, improved patient access to treatment, and enhanced competition within the pharmaceutical sector.
The provision also supports innovation by allowing companies to prepare improved manufacturing processes and regulatory strategies without infringing patent rights. From a public health perspective, the Bolar Provision is particularly important in a country like India, where access to affordable medicines remains a significant concern. Delayed market entry of generic products can result in prolonged periods of high drug prices and limited access to essential treatments. By facilitating immediate post-patent competition, Section 107A promotes the objectives of public welfare and healthcare accessibility.
The provision also aligns with international obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Although TRIPS requires member states to provide patent protection, it also permits certain limited exceptions that do not unreasonably conflict with the normal exploitation of patents or prejudice the legitimate interests of patent holders. The Bolar Exception is widely regarded as a TRIPS-compliant measure because it strikes a balance between private intellectual property rights and broader societal interests. Despite its benefits, the Bolar Provision is not without controversy.
Patent holders often express concerns that the exemption may be abused by competitors engaging in activities that go beyond regulatory requirements. Determining whether an activity is genuinely related to obtaining regulatory approval or constitutes disguised commercial exploitation can be a complex factual inquiry. Courts must carefully examine evidence regarding the purpose, scale, and nature of the activities undertaken. Excessive production, stockpiling of products for future commercial sale, or large-scale distribution unrelated to regulatory requirements may fall outside the scope of the exemption and attract liability for infringement. Consequently, judicial oversight plays a crucial role in maintaining the integrity of the Bolar Provision while preventing misuse.
Another important aspect of Section 107A is that it serves as a statutory defence in patent infringement suits. When a patent holder alleges infringement, the defendant may invoke the Bolar Exception by demonstrating that the impugned activities were undertaken solely for purposes reasonably related to the development and submission of information required under regulatory laws. If the defence is successfully established, the activities are deemed non-infringing regardless of whether they would otherwise fall within the exclusive rights granted under Section 48 of the Patents Act. This statutory protection provides legal certainty to generic manufacturers and encourages investment in research and regulatory compliance.
The Bolar Provision also reflects India’s broader approach to patent law, which seeks to balance incentives for innovation with public interest considerations. Similar policy objectives can be observed in provisions relating to compulsory licensing, research exemptions, and restrictions on evergreening of pharmaceutical patents. Together, these measures contribute to a patent system that promotes innovation while safeguarding access to technology and healthcare. In the context of globalization and increasing regulatory complexity, the importance of the Bolar Exception is likely to grow further.
Pharmaceutical products, medical devices, biotechnology inventions, agrochemical products, and other regulated technologies often require extensive approval processes across multiple jurisdictions. The ability to undertake preparatory activities during the patent term enhances efficiency, reduces delays, and supports international competitiveness. In conclusion, the Bolar Provision embodied in Section 107A of the Patents Act, 1970 represents a critical defence to patent infringement suits in India and serves as a cornerstone of the country’s intellectual property framework.
By permitting activities reasonably related to obtaining regulatory approval, the provision prevents unintended extensions of patent monopolies, facilitates prompt market entry of generic products, promotes competition, enhances access to affordable medicines, and supports public health objectives. Judicial interpretations have consistently emphasized the need to balance the rights of patent holders with the broader interests of society, ensuring that the exemption remains effective while preventing abuse. As innovation, regulation, and global commerce continue to evolve, the Bolar Provision will remain an essential mechanism for harmonizing patent protection with economic development, technological progress, and public welfare in India.
Leave a Reply